Published: Friday, May 24, 2024 · 5:06 PM | Updated: Friday, May 24, 2024 · 5:06 PM
📊 633 views
May 23, 2024 / 12:30PM GMT
Renee Aguiar–Lucander – Calliditas Therapeutics AB – Chief Executive Officer
Welcome to this Q1 2024 report from Calliditas Therapeutics. My name is Renee Aguiar-Lucander. I’m the CEO of the company, and I’m today joined by Fredrik Johansson, our Chief Financial Officer; Richard Philipson, our Chief Medical Officer; and Maria Tornsen, our President of North America. Next page please.
I would like to draw your attention to the disclaimer notice which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended and I refer to public filings including those containing risk factors. Next page, please.
So I would like to take you through some of our Q1 highlights, which included the appointment of Maria Tornsen as President of North America, who brings over 10 years of rare disease experience to Calliditas including multiple product launches, both in the US and ex-US.
Following our full approval in December last year, we were able to roll out new marketing materials to a fully trained field team in February,
MORE IN INSIDE INVESTMENT NEWS
AI Funding Fears Rattle Wall Street: Adjusting for Alpha and Preservation
Published: Saturday, October 24, 2026 · 12:28 PM
Volvo Cars Plunge: Alpha Warning as China Sales Slump Hits Earnings
Published: Friday, October 23, 2026 · 6:18 AM
